What is PEG-MGF? What it does, benefits and what the evidence shows

PEG-MGF is sold as a pegylated (polyethylene glycol-attached) version of mechano growth factor, or MGF, a short peptide taken from a splice variant of the IGF-1 gene that switches on in stretched or damaged muscle. The pitch is muscle repair and growth. The evidence is thin: the supporting work is on plain MGF peptides in cultured cells and animals, researchers at two pharmaceutical companies could not reproduce the headline cell result in a 2014 study, and a 2026 narrative review in Frontiers in Endocrinology found no peer-reviewed human studies of PEG-MGF at all.

What PEG-MGF and MGF are

The IGF-1 gene can be spliced into several versions. One of them, IGF-1Ec in humans (IGF-1Eb in rodents), was named mechano growth factor because its expression rises in muscle under mechanical stress (Thevis et al., Growth Hormone & IGF Research, 2014). In rat muscle it spiked within days of damage and then faded as the main IGF-1 variant took over (Hill and Goldspink, Journal of Physiology, 2003). The "MGF peptide" that gets sold is not that whole protein. It is a synthetic peptide matching the 24 most C-terminal amino acids of the E-domain (Matheny et al., Endocrinology, 2010).

PEG-MGF adds polyethylene glycol to that peptide. The stated rationale is to make it more stable and keep it around longer, but the research usually cited for "MGF-like" effects is based on native IGF-1Ec biology and synthetic E-domain peptides, not on PEG-MGF as a characterized drug. The same review points out that pegylation changes how a molecule moves through the body, so results with the plain peptide cannot be assumed to carry over (Dominikowski et al., Frontiers in Endocrinology, 2026). We did not find a peer-reviewed study of PEG-MGF itself in muscle.

Plain MGF is the more studied of the two, and it has a wrinkle: the peptide exists in the lab, but no one has established that the body makes it. A 2010 review noted that no analogous peptide product of the IGF-1 gene had been identified in cells, culture medium, tissues or fluids (Matheny et al., 2010), and a 2012 commentary said the same question was still open (Zabłocka et al., Frontiers in Endocrinology, 2012).

What people use it for

What the research actually shows

Muscle repair: a split result

The original claim came from a 2002 cell study: the MGF E-domain increased myoblast (muscle precursor cell) proliferation while inhibiting their final differentiation, unlike mature IGF-1, and it appeared to work through a different receptor (Yang and Goldspink, FEBS Letters, 2002). A 2011 study on primary human muscle cell cultures found the MGF peptide extended the proliferative lifespan of satellite cells from neonatal and young adult donors but not from old donors, and the authors suggested it might help against age-related muscle loss (Kandalla et al., Mechanisms of Ageing and Development, 2011). In mice, injecting a synthetic MGF peptide into muscle or delivering it systemically improved how well transplanted human muscle precursor cells took hold (Mills et al., American Journal of Transplantation, 2007).

Then came a replication attempt. Researchers at two pharmaceutical companies tried to reproduce the effect and reported that MGF peptides, including a stabilized version, failed to increase proliferation of mouse or human myoblasts, failed to block differentiation, and did not activate ERK signaling in heart cells as previously reported, while mature IGF-1 and full-length IGF-1Eb did increase proliferation, and IGF-1 did activate ERK. They concluded that the results "call in to question whether there is a physiological role for MGF" (Fornaro et al., American Journal of Physiology, Endocrinology and Metabolism, 2014). Neither side has closed the argument. What you can say honestly is that the foundational muscle-cell result is disputed.

What happens in people

The human data is about the body's own MGF, not the injected peptide. In a 2003 study of eight young (25-36) and seven elderly (70-82) people, MGF mRNA in thigh muscle biopsies taken 2.5 hours after a hard single-leg exercise session rose in the young but not in the elderly, while IGF-1Ea mRNA did not change in either group (Hameed et al., Journal of Physiology, 2003). That is a measurement of what the muscle does after training. It says nothing about whether giving someone a synthetic peptide builds muscle. The 2026 review sorts PEG-MGF into its lowest evidence tier, with no peer-reviewed human studies and only preclinical extrapolation (Dominikowski et al., 2026).

Heart studies in mice

Two mouse studies gave an MGF E-domain peptide around the time of a heart attack. Both reported better heart function and less pathological remodeling than in untreated mice, one embedding the peptide in tiny polymer rods and the other simply giving it at the time of the heart attack (Peña et al., Biomaterials, 2015; Mavrommatis et al., Molecular and Cellular Biochemistry, 2013). Both came from the same senior author's lab, and both are in mice.

Recovery, injuries and fat loss

We found no human study of PEG-MGF or plain MGF for fat loss, tendon or joint injury recovery, or general training recovery, and no registration of a PEG-MGF trial on ClinicalTrials.gov. Treat those claims as anecdotal.

Side effects and risks

Nobody knows the human side-effect profile, because there are no human trials to draw one from. What we can say:

• FDA's view. PEG-MGF appears on FDA's page of bulk drug substances that were flagged for safety risk and then withdrawn by the nominators. FDA writes that compounded PEG-MGF "may pose significant risk for immunogenicity for certain routes of administration," notes complexities with peptide-related impurities and characterization, and says it has not identified any human exposure data on PEG-MGF products by any route (FDA, page current as of April 22, 2026). Withdrawn there does not mean FDA has cleared it.
• A growth signal you probably do not want. In human prostate tissue, MGF was found to be preferentially expressed in cancerous tissue compared with normal tissue, and a synthetic MGF E peptide stimulated the growth of prostate cancer cell lines in dishes, apparently without needing the IGF-1 receptor (Armakolas et al., The Prostate, 2010). This is cell work, not evidence that the injected peptide causes cancer in people; the 2026 review calls the concern theoretical and preclinical (Dominikowski et al., 2026). It does mean "more growth signaling" is not automatically a harmless idea.
• Product identity. In 2014, anti-doping scientists characterized a "full-length MGF" being offered through illicit channels and found a protein with a modified C-terminus and an amino acid substitution relative to IGF-1Ec (Thevis et al., Growth Hormone & IGF Research, 2014). That was one product, not a survey, but it shows that what is sold under an MGF label can differ from what the papers studied.
• Sport. "Mechano growth factors (MGFs)" are named on the World Anti-Doping Agency's 2026 Prohibited List under peptide hormones and growth factors, prohibited at all times (WADA Prohibited List 2026).

What the lab tests show

As of September 29, 2026, VendorVerify's database has no lab results for PEG-MGF or for plain MGF. That doesn't mean the vials are good or bad; it means no report has been submitted that we can count. PEG-MGF is a trickier item to verify than most: FDA itself notes complexities in characterizing it, so an identity and purity report is harder to read than for a plain peptide, and it is worth asking the lab up front how it will measure it. If you have had a PEG-MGF vial tested, submitting the report is the fastest way to change that.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

With no compound-specific data, lean on the general checks. Look at each vendor's full record and how many reports sit behind the score. Treat a vendor-posted COA as a starting point (how to read a peptide COA, fake peptide COAs). For a compound with no track record in our data and a product form (pegylated) that varies, paying for testing on your own vial is worth it; how to get a peptide tested walks through it, and endotoxin in research peptides covers when to add that test.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. Buyers who read about PEG-MGF often also look at IGF-1 LR3, TB-500 and BPC-157; the peptide hub lists every compound we track.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice; PEG-MGF is unapproved, sold for research use only, and has no published human studies we could find.